Jill M. Broadfoot

2022 - aTYR PHARMA

In 2022, Jill M. Broadfoot earned a total compensation of $913.5K as Chief Financial Officer at aTYR PHARMA, which was about the same as previous year.

Compensation breakdown

Non-Equity Incentive Plan$132,610
Option Awards$274,076
Salary$414,395
Stock Awards$82,800
Other$9,612
Total$913,493

Broadfoot received $414.4K in salary, accounting for 45% of the total pay in 2022.

Broadfoot also received $132.6K in non-equity incentive plan, $274.1K in option awards, $82.8K in stock awards and $9.6K in other compensation.

Rankings

In 2022, Jill M. Broadfoot's compensation ranked 3,232nd out of 5,756 executives tracked by ExecPay. In other words, Broadfoot earned more than 43.8% of executives.

ClassificationRankingPercentile
All
3,232
out of 5,756
44th
Division
Manufacturing
1,815
out of 3,133
42nd
Major group
Chemicals And Allied Products
864
out of 1,419
39th
Industry group
Drugs
808
out of 1,320
39th
Industry
Biological Products, Except Diagnostic Substances
193
out of 291
34th
Source: SEC filing on April 5, 2024.

Broadfoot's colleagues

We found two more compensation records of executives who worked with Jill M. Broadfoot at aTYR PHARMA in 2022.

2022

Sanjay Shukla

aTYR PHARMA

Chief Executive Officer

2022

Nancy Denyes

aTYR PHARMA

General Counsel

News

You may also like